

Consensus WCHA 2025-26 Respiratory Virus Season Immunization Recommendations

The West Coast Health Alliance (WCHA) is issuing immunization recommendations for the 2025-2026 respiratory virus season. These recommendations are informed by trusted national medical organizations, including the [American Academy of Pediatrics](#) (AAP), the [American College of Obstetricians and Gynecologists](#) (ACOG), and the [American Academy of Family Physicians](#) (AAFP). The WCHA believes that all recommended immunizations should be accessible to the people of our states.

Immunization is safe, effective, and the best protection available against respiratory viruses such as COVID-19, influenza, and RSV. Seasonal immunization is also a critical public health tool to reduce serious illness, community transmission, and health care systems strain.

WCHA recommendations are based on data regarding the people most impacted by these respiratory viruses, especially our most vulnerable. This includes: the youngest and oldest individuals in our states; other individuals at higher risk for complications, including people who are pregnant; individuals living in congregate settings; and those who live or work with people at higher risk. The WCHA will continue to evaluate new evidence and recommendations as they become available and is committed to sharing any updated assessments with our communities.

The WCHA reviewed COVID-19 epidemiology, vaccine effectiveness, safety data, and national medical organization recommendations to arrive at the consensus recommendations. Individuals with risk factors for severe COVID-19 infection, including age, underlying medical conditions, unvaccinated status, and congregate living facility residence were recommended to receive an updated 2025-26 COVID-19 vaccine. No new safety concerns were reported since the last thorough review. COVID-19 vaccines continue to protect individuals from hospitalization and death. WCHA recommendations have been adopted by the Oregon Immunization Program.

Consensus WCHA 2025-26 Respiratory Virus Season Immunization Recommendations

Age/Condition	COVID-19	Influenza	RSV
Children	<ul style="list-style-type: none"> All 6-23 months All 2-18 years with risk factors or never vaccinated against COVID-19 All who are in close contact with others with risk factors All who choose protection^a 	<ul style="list-style-type: none"> All 6 months and older 	<ul style="list-style-type: none"> All younger than 8 months^b All 8-19 months with risk factors^c
Pregnancy	<ul style="list-style-type: none"> All who are planning pregnancy, pregnant, postpartum or lactating 	<ul style="list-style-type: none"> All who are planning pregnancy, pregnant, postpartum or lactating 	<ul style="list-style-type: none"> 32-36 weeks gestational age^b
Adults	<ul style="list-style-type: none"> All 65 years and older All younger than 65 years with risk factors All who are in close contact with others with risk factors All who choose protection 	<ul style="list-style-type: none"> All 	<ul style="list-style-type: none"> All 75 years and older^d All 50-74 years with risk factors^{d,e}

^a COVID-19 vaccine is available for persons 6 months of age and older.

^b Protect infants with either prenatal RSV vaccine or infant dose of nirsevimab or clesrovimab.

^c Effective September 15, 2025, see <https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/infants-young-children.html> for additional information on risk factors for severe RSV disease in children 8-19 months.

^d Adult RSV immunization recommendations are currently for a single lifetime dose. Those who have previously received a dose do not need a second dose.

^e Effective September 15, 2025, see <https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/adults.html> for additional information on risk factors for severe RSV disease in adults 50-74 years.